Hydrocortisone Plus Aminoglutethimide or Ketoconazole in Treating Patients With Localized Stage IV Prostate Cancer
Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Prostate Cancer
Intervention: aminoglutethimide (Drug); ketoconazole (Drug); therapeutic hydrocortisone (Drug)
Phase: Phase 2
Status: Active, not recruiting
Sponsored by: H. Lee Moffitt Cancer Center and Research Institute
Official(s) and/or principal investigator(s):
Mayer Fishman, MD, PhD, Study Chair, Affiliation: H. Lee Moffitt Cancer Center and Research Institute
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as
aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones.
Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective
treatment for prostate cancer.
PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either
aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate
Official title: A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
Study design: Treatment
OBJECTIVES: I. Determine the PSA response proportion and duration of response of patients
with localized stage IV (D0. 5) adenocarcinoma of the prostate treated with early medical
adrenalectomy using hydrocortisone combined with aminoglutethimide or ketoconazole after
prior antiandrogen withdrawal. II. Compare the incidence of grades 3-4 toxicities of these
regimens in these patients. III. Correlate adrenal androgen suppression with response in
OUTLINE: Patients are stratified according to prior antiandrogen therapy (yes vs no).
Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen
withdrawal, while those without such prior therapy begin study therapy immediately. Patients
undergo medical adrenalectomy using hydrocortisone combined with aminoglutethimide OR
ketoconazole. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is
administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral
ketoconazole is administered three times daily. Combination treatment continues in the
absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Minimum age: N/A.
Maximum age: N/A.
DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the prostate Stage IV
(D0. 5; no evidence of disease on CT or bone scan after testicular androgen ablation) PSA
progression after testicular androgen ablation with or without antiandrogen therapy
Progression is defined as at least 2 consecutive rising PSA levels (drawn at least 2 weeks
apart) with a greater than 50% rise above the last nadir level (arbitrary PSA at least 2
PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:
Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
Other: No other medical conditions that would increase risk Fertile patients must use
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
Endocrine therapy: See Disease Characteristics Greater than 4 weeks since prior flutamide
(6 weeks for bicalutamide or nilutamide) No prior aminoglutethimide or ketoconazole for
prostate cancer Continuation of primary testicular androgen suppression (i. e., LHRH analog)
required Radiotherapy: Not specified Surgery: Not specified Other: No concurrent
terfenadine, astemizole, cisapride, or other medicines known to interact with ketoconazole
Locations and Contacts
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, United States
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: May 2000
Last updated: May 23, 2008